Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arcutis Biotherapeutics Inc.

16.77
+0.17001.02%
Post-market: 16.68-0.0935-0.56%16:17 EDT
Volume:3.29M
Turnover:55.73M
Market Cap:1.99B
PE:-14.48
High:17.50
Open:16.70
Low:16.63
Close:16.60
Loading ...

Arcutis Biotherapeutics Inc - Elected Keith Leonard as Chair of Board Effective November 4

THOMSON REUTERS
·
07 Nov 2024

Arcutis Biotherapeutics Q3 Operating Expenses USD 83.821 Million

THOMSON REUTERS
·
07 Nov 2024

High Growth Tech Stocks In The United States To Watch

Simply Wall St.
·
07 Nov 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Nov 2024

Arcutis Biotherapeutics: Resilient Growth and Market Penetration Drive Buy Rating

TIPRANKS
·
04 Nov 2024

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks
·
28 Oct 2024

Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Zacks
·
25 Oct 2024

Buy Rating Reaffirmed for Arcutis Biotherapeutics Amid Temporary Challenges and Strong Zoryve Sales Forecast

TIPRANKS
·
23 Oct 2024

Arcutis Biotherapeutics' Zoryve Approved to Treat Seborrheic Dermatitis in Canada

MT Newswires Live
·
21 Oct 2024

Arcutis Canada Announces Health Canada Approval of Zoryve® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

THOMSON REUTERS
·
21 Oct 2024

Arcutis Biotherapeutics Receives Approval in Canada for Skin Disease Cream Zoryve

MT Newswires Live
·
18 Oct 2024

Arcutis Biotherapeutics receives Health Canada approval of ZORYVE Foam 0.3%

TIPRANKS
·
18 Oct 2024

BRIEF-Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

Reuters
·
18 Oct 2024

Arcutis Announces Health Canada Approval of Zoryve® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

THOMSON REUTERS
·
18 Oct 2024

Arcutis Biotherapeutics (ARQT) Gets a Buy from Mizuho Securities

TIPRANKS
·
14 Oct 2024

Arcutis Biotherapeutics, Inc (ARQT): A Small-Cap Leader in Skin Disease Treatments

Insider Monkey
·
12 Oct 2024